Small India drugmakers struggle to meet US rules
They are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals
Mumbai
INDIA'S smaller generic drugmakers, struggling to cope with a bruised reputation and tougher regulation in the United States, are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals.
Two years after its most high-profile regulatory setback to date in the US - Ranbaxy's US$500 million fine for drug safety violations - India's US$15 billion a year generic drug industry is still rebuilding its image in its biggest market.
Many of its top firms are facing sanctions at some of their factories, as the US Food and Drug Administration (FDA) tightens checks and…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Abbott beats quarterly profit estimates on strong medical device sales
Adidas shares surpass two-year high as 'terrace' sneaker trend boosts brand heat
LVMH’s first quarter sales growth slips to 3% on luxury slowdown
US Justice Department to file antitrust suit against Live Nation: WSJ
EU set to launch China probe on medical device procurement
Muji bets its minimalist retail will work for homes, hotels